Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $317,579.13 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $26.73, for a total transaction of $317,579.13. Following the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at approximately $10,098,647.46. The trade was a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07.
• On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total transaction of $338,014.45.
• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total transaction of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total transaction of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total transaction of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total transaction of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.
• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.66, for a total value of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $29.19, for a total value of $346,806.39.

Adaptive Biotechnologies Trading Up 3.0%

Adaptive Biotechnologies stock traded up $0.74 during trading hours on Tuesday, hitting $25.80. The stock had a trading volume of 1,494,257 shares, compared to its average volume of 2,050,401. The company has a 50-day moving average of $26.37 and a two-hundred day moving average of $19.71. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $30.74.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. Piper Sandler lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Morgan Stanley increased their price objective on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, October 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.06.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently added to or reduced their stakes in the stock. Nykredit A S bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at approximately $31,000. Allworth Financial LP acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $35,000. Integrated Wealth Concepts LLC bought a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $46,000. KBC Group NV bought a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $45,000. Finally, Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 46.4% in the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after buying an additional 1,401 shares in the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.